Pfizer-BioNTech COVID-19 Vaccine Elicits Response Against Key Mutation
Antibodies elicited from the Pfizer-BioNTech COVID-19 vaccine can effectively neutralize SARS-CoV-2 with the mutation associated with rapid transmission.
Antibodies elicited from the Pfizer-BioNTech COVID-19 vaccine can effectively neutralize SARS-CoV-2 with the mutation associated with rapid transmission.
Additional research from the vaccine manufacturers would be needed to support any changes to the dosing schedule.
Moderna is increasing its baseline production estimates for its COVID-19 vaccine from 500 to 600 million doses for 2021.
The FDA has granted an EUA to Moderna’s COVID-19 vaccine, mRNA-1237, for active immunization.
The investigational treatment from Regeneron consists of 2 potent, virus-neutralizing antibodies.
RediTrex is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis.
A phase 3 trial evaluating the vaccine candidate mRNA-1273 against COVID-19 met its primary efficacy end point in the first interim analysis.
AstraZeneca has resumed a phase 3 clinical trial investigating AZD1222, its COVID-19 vaccine candidate.
The FDA has issued an Emergency Use Authorization (EUA) for the use of COVID-19 convalescent plasma.
The FDA has issued a CRL to Gilead Sciences related to the NDA for filgotinib in the treatment of moderately to severely active rheumatoid arthritis.